Clinical trial
Study to Determine the Response and Effectiveness of RSD1235 in Subjects With…
NCT00115791 · Astellas Pharma Inc, Industry · Completed
Key facts
| NCT number | NCT00115791 |
|---|---|
| Title | Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter |
| Official title | A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Tolerance and Efficacy Study of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter |
| Lead sponsor | Astellas Pharma Inc, Industry |
| Collaborators | Advanz Pharma Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Atrial Flutter, Atrial Fibrillation |
| Intervention type | Drug |
| Interventions | RSD1235, placebo |
| Enrollment | 276 |
| Start date | Jun 1, 2004 |
| Primary completion | Jun 1, 2005 |
| Completion | Jun 1, 2005 |
| First posted | Jun 27, 2005 |
| Last update posted | Apr 1, 2008 |
| Countries | Argentina, Canada, Chile, Denmark, Mexico, Sweden, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: